Denya Sanchez-Quintero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Denya Sanchez-Quintero has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Arantza Marie Perez-Partida
National Institute of Cardiology Ignacio Chavez, Juan Badiano 1, Belisario Dominguez Secc 16, Tlalpan, Mexico City 14080, Mexico
1 shared publication - Erick Alexanderson-Rosas
National Institute of Cardiology Ignacio Chavez, Juan Badiano 1, Belisario Dominguez Secc 16, Tlalpan, Mexico City 14080, Mexico
1 shared publication - Javier Iván Armenta Moreno
Centro de Investigación en Ciencias de la Salud (CICSA), Facultad de Ciencias de la Salud Universidad Anáhuac México Norte, Huixquilucan 52786, Mexico
1 shared publication - Joaquin Berarducci
Instituto Nacional de Cardiología Ignacio Chávez
1 shared publication - Jorge Luis Bermudez-Gonzalez
Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico
1 shared publication - Jose Antonio Luna-Alvarez-Amezquita
National Institute of Cardiology Ignacio Chavez, Juan Badiano 1, Belisario Dominguez Secc 16, Tlalpan, Mexico City 14080, Mexico
1 shared publication
Latest Publications
- Open Access
- 25 March 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (4) , 627
Role of the Antioxidant Activity of Melatonin in Myocardial Ischemia-Reperfusion Injury
Ischemia-reperfusion injury is a common problem in the age of interventional cardiology; it is primarily mediated by oxidative stress and reactive agents. Melatonin has antioxidative properties that make its use promising for treating ischemia-reperfusion injury. Multiple experimental studies in murine and porcine models have been performed with good results. Clinical trials have also been conducted but given their heterogeneity, no conclusive results can be made. Melatonin pharmacokinetic properties are not ideal; therefore, many analogs have been proposed with improved characteristics, and some studies have evaluated their efficacy in animal models, but clinical trials are needed to recommend their use. In this review, we expose the results of the most impactful studies regarding melatonin use in ischemia-reperfusion injury.
- 25 March 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (4) , 627
Open AccessRole of the Antioxidant Activity of Melatonin in Myocardial Ischemia-Reperfusion Injury
Ischemia-reperfusion injury is a common problem in the age of interventional cardiology; it is primarily mediated by oxidative stress and reactive agents. Melatonin has antioxidative properties that make its use promising for treating ischemia-reperfusion injury. Multiple experimental studies in murine and porcine models have been performed with good results. Clinical trials have also been conducted but given their heterogeneity, no conclusive results can be made. Melatonin pharmacokinetic properties are not ideal; therefore, many analogs have been proposed with improved characteristics, and some studies have evaluated their efficacy in animal models, but clinical trials are needed to recommend their use. In this review, we expose the results of the most impactful studies regarding melatonin use in ischemia-reperfusion injury.